Issues related to patient access and pricing. Issues related to policy changes to Medicare Part D. Issues related to 340B reform. Issues related to the EPIC (Ensuring Pathways to Innovative Cures) Act, H.R.1492/S.832. Issues related to Most Favored Nation (MFN) policy. Issues related to PBM reform.
2025 · 3rd Quarter (July 1 - Sep 30)
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA)
Filed by DESIMONE CONSULTING, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 16, 2025
- Income
- $30,000.00
- Expenses
- Not reported
- Registrant
- DESIMONE CONSULTING, LLC
- Filing UUID
- 8f195b95-1257-4ed9-9e31-736160a8220c
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.